Search for a doctor

Steven R. Alberts, M.D., M.P.H.

  1. Oncologist
  2. Chair, Medical Oncology, Minnesota
Request an Appointment

Publications

  1. Gallois C, Shi Q, Pederson LD, Andre T, Iveson TJ, Sobrero AF, Alberts S, de Gramont A, Meyerhardt JA, George T, Schmoll HE, Souglakos I, Harkin A, Labianca R, Sinicrope FA, Oki E, Shields AF, Boukovinas I, Kerr R, Lonardi S, Yothers G, Yoshino T, Goldberg RM, Taieb J, Papamichael D. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials. J Clin Oncol. 2024 Jul 1; 42 (19):2295-2305 Epub 2024 Mar 28
    View PubMed
  2. Sinicrope FA, Nelson GD, Saberzadeh-Ardestani B, Segovia DI, Graham RP, Wu C, Hagen CE, Shivji S, Savage P, Buchanan DD, Jenkins MA, Phipps AI, Swallow C, LeMarchand L, Gallinger S, Grant RC, Pai RK, Sinicrope SN, Yan D, Shanmugam K, Conner J, Cyr DP, Kirsch R, Banerjee I, Alberts SR, Shi Q, Pai RK. Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence. Cancer Res Commun. 2024 May 23; 4 (5):1344-1350
    View PubMed
  3. Desai A, Xiao AH, Choi D, Toruner MD, Walden D, Halfdanarson TR, Alberts S, McWilliams RR, Mahipal A, Ahn D, Babiker H, Stybayeva G, Revzin A, Kizilbash S, Adjei A, Bekaii-Saab T, Mansfield AS, Carr RM, Ma WW. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2024 May 13; 16 (10)
    View PubMed
  4. Tevaarwerk AJ, Karam D, Gatten CA, Harlos ES, Maurer MJ, Giridhar KV, Haddad TC, Alberts SR, Holton SJ, Stockham A, Leventakos K, Hubbard JM, Mansfield AS, Halfdanarson TR, Chen R, Jochum JA, Schwecke AS, Eiring RA, Carroll JL, Riaz IB, McWilliams RR, Galanis E, Mandrekar SJ. Transforming the oncology data paradigm by creating, capturing, and retrieving structured cancer data at the point of care: A Mayo Clinic pilot. Cancer. 2024 Apr 25 [Epub ahead of print]
    View PubMed
  5. Taieb J, Sinicrope FA, Pederson L, Lonardi S, Alberts SR, George TJ, Yothers G, Van Cutsem E, Saltz L, Ogino S, Kerr R, Yoshino T, Goldberg RM, Andre T, Laurent-Puig P, Shi Q. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials. Ann Oncol. 2023 Nov; 34 (11):1025-1034 Epub 2023 Aug 23
    View PubMed
  6. Park HA, Edelmann D, Canzian F, Seibold P, Harrison TA, Hua X, Shi Q, Silverman A, Benner A, Macauda A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients. Int J Cancer. 2023 Nov 1; 153 (9):1623-1634 Epub 2023 Aug 04
    View PubMed
  7. Tella SH, Foster N, Qian S, Nguyen T, Borad MJ, McWilliams RR, Alberts SR, Wee Ma W, Chakrabarti S, Fruth B, Wessling J, Hartgers M, Washburn L, Fernandez-Zapico ME, Hogenson TL, Pitot H, Jin Z, Mahipal A. Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2023 Oct 3; 28 (10):917-e966
    View PubMed
  8. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2023 Jul 20; 41 (21):3670-3675
    View PubMed
  9. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. J Clin Oncol. 2023 Jul 1; 41 (19):3461-3468
    View PubMed
  10. Anyidoho PA, Verschraegen CF, Markham MJ, Alberts S, Sweetenham J, Cameron K, Abu Hejleh T. Impact of the Immediate Release of Clinical Information Rules on Health Care Delivery to Patients With Cancer. JCO Oncol Pract. 2023 May; 19 (5):e706-e713 Epub 2023 Feb 13
    View PubMed
  11. Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, Andre T, Papamichael D, Taieb J. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. J Clin Oncol. 2023 Feb 1; 41 (4):803-815 Epub 2022 Oct 28
    View PubMed
  12. McGarrah P, Hubbard J, Novotny PJ, Branda ME, Sargent DS, Morton RF, Fuchs CS, Benson AB, Williamson SK, Findlay BP, Alberts SR, Goldberg RM, Sloan JA. Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer. Cancer Control. 2023 Jan-Dec; 30:10732748231185047
    View PubMed
  13. Park HA, Edelmann D, Canzian F, Harrison TA, Hua X, Shi Q, Silverman A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis. Cancer Epidemiol Biomarkers Prev. 2022 Nov 2; 31 (11):2087-2091
    View PubMed
  14. Saberzadeh-Ardestani B, Foster NR, Lee HE, Shi Q, Alberts SR, Smyrk TC, Sinicrope FA. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]. Ann Oncol. 2022 Nov; 33 (11):1159-1167 Epub 2022 Aug 10
    View PubMed
  15. Gile JJ, Wookey V, Zemla TJ, Shi Q, Jin Z, Alberts SR, McWilliams RR, Ma WW, Borad M, Bekaii-Saab TS, Tran NH, Mahipal A. Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma. Target Oncol. 2022 Sep; 17 (5):529-538 Epub 2022 Sept 02
    View PubMed
  16. Sinicrope FA, Shi Q, Catteau A, Poage GM, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. JCO Precis Oncol. 2022 Aug; 6:e2200010
    View PubMed
  17. Halfdanarson TR, Foster NR, Kim GP, Haddock MG, Dakhil SR, Behrens RJ, Alberts SR. N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma. Oncologist. 2022 Jul 5; 27 (7):534-e546
    View PubMed
  18. Christou N, Bergen ES, Canton C, Le Malicot K, Di Bartolomeo M, Galli F, Galli F, Labianca R, Shi Q, Alberts SR, Goldberg RM, Lepage C, Sinicrope FA, Taieb J. Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials. Eur J Cancer. 2022 May; 166:100-111 Epub 2022 Mar 11
    View PubMed
  19. Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, DeGramont A, Van Cutsem E, Taieb J, Alberts SR, Wolmark N, Schmoll HJ, Saltz LB, George TJ, Goldberg RRM, Kerr R, Lonardi S, Yoshino T, Yothers G, Grothey A, Andre T, Shi Q. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. J Natl Cancer Inst. 2022 Jan 11; 114 (1):60-67
    View PubMed
  20. Patel JN, Jiang C, Owzar K, Mulkey F, Luzum JA, Mamon HJ, Haller DG, Dragovich T, Alberts SR, Bjarnason G, Willet CG, Niedzwiecki D, Enzinger P, Ratain MJ, Fuchs C, McLeod HL. Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenet Genomics. 2021 Dec 1; 31 (9):215-220
    View PubMed
  21. Wills C, He Y, Summers MG, Lin Y, Phipps AI, Watts K, Law PJ, Al-Tassan NA, Maughan TS, Kaplan R, Houlston RS, Peters U, Newcomb PA, Chan AT, Buchanan DD, Gallinger S, Marchand LL, Pai RK, Shi Q, Alberts SR, Gray V, West HD, Escott-Price V, Dunlop MG, Cheadle JP. A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. Eur J Cancer. 2021 Dec; 159:247-258 Epub 2021 Nov 15
    View PubMed
  22. Sinicrope FA, Shi Q, Smyrk TC, Goldberg RM, Cohen SJ, Gill S, Kahlenberg MS, Nair S, Shield AF, Jahagirdar BN, Jacobson SB, Foster NR, Pollak MN, Alberts SR. Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. JNCI Cancer Spectr. 2021 Oct; 5 (5) Epub 2021 July 23
    View PubMed
  23. Tran NH, Foster NR, Mahipal A, Byrne T, Hubbard J, Silva A, Mody K, Alberts S, Borad MJ. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Invest New Drugs. 2021 Aug; 39 (4):1072-1080 Epub 2021 Mar 01
    View PubMed
  24. Hua X, Dai JY, Lindstrom S, Harrison TA, Lin Y, Alberts SR, Alwers E, Berndt SI, Brenner H, Buchanan DD, Campbell PT, Casey G, Chang-Claude J, Gallinger S, Giles GG, Goldberg RM, Gunter MJ, Hoffmeister M, Jenkins MA, Joshi AD, Ma W, Milne RL, Murphy N, Pai RK, Sakoda LC, Schoen RE, Shi Q, Slattery ML, Song M, White E, Marchand LL, Chan AT, Peters U, Newcomb PA. Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study. Cancer Epidemiol Biomarkers Prev. 2021 Jul; 30 (7):1349-1358 Epub 2021 May 10
    View PubMed
  25. Yoon HH, Ou FS, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Ginos B, Heying E, Wu TT, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP, Alberts SR. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). Eur J Cancer. 2021 Jun; 150:214-223 Epub 2021 Apr 29
    View PubMed
  26. Ma WW, Zhu M, Lam ET, Diamond JR, Dy GK, Fisher GA, Goff LW, Alberts S, Bui LA, Sanghal A, Kothekar M, Khopade A, Chimote G, Faulkner R, Eckhardt SG, Adjei AA, Jimeno A. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. Cancer Chemother Pharmacol. 2021 Jun; 87 (6):779-788 Epub 2021 Feb 26
    View PubMed
  27. Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O'Connell MJ, Twelves C, Taieb J, Saltz LB, Blanke CD, Francini E, Kerr R, Yothers G, Seitz JF, Marsoni S, Goldberg RM, Shi Q. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. J Natl Cancer Inst. 2021 Apr 6; 113 (4):400-407
    View PubMed
  28. Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz JF, O'Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, Lonardi S, Kerr R, Grothey A, Sinicrope FA, Andre T, Shi Q. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol. 2021 Feb 20; 39 (6):642-651 Epub 2020 Dec 23
    View PubMed
  29. Labadie JD, Hua X, Harrison TA, Banbury BL, Huyghe JR, Sun W, Shi Q, Yothers G, Alberts SR, Sinicrope FA, Goldberg RM, George TJ, Penney KL, Phipps AI, Cohen SA, Peters U, Chan AT, Newcomb PA. Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev. 2021 Feb; 30 (2):404-411 Epub 2020 Nov 17
    View PubMed
  30. Francini E, Ou FS, Lazzi S, Petrioli R, Multari AG, Pesola G, Messuti L, Colombo E, Livellara V, Bazzurri S, Cherri S, Miano ST, Wolfe EG, Alberts SR, Hubbard JM, Yoon HH, Francini G. The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. Transl Oncol. 2021 Feb; 14 (2):100973 Epub 2020 Dec 15
    View PubMed
  31. Sinicrope FA, Chakrabarti S, Laurent-Puig P, Huebner L, Smyrk TC, Tabernero J, Mini E, Goldberg RM, Zaanan A, Folprecht G, Van Laethem JL, Le Malicot K, Shi Q, Alberts SR, Taieb J. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. Eur J Cancer. 2021 Feb; 144:101-112 Epub 2020 Dec 17
    View PubMed
  32. Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021; 5 Epub 2021 July 28
    View PubMed
  33. Tella SH, Kommalapati A, Alberts SR, McWilliams R, Mahipal A. Collateral damage of COVID-19 pandemic on oncology clinical trials. Chin Clin Oncol 2020 Dec; 9 (6):80 Epub 2020 Nov 18
    View PubMed
  34. Penney KL, Banbury BL, Bien S, Harrison TA, Hua X, Phipps AI, Sun W, Song M, Joshi AD, Alberts SR, Allegra CJ, Atkins J, Colangelo LH, George TJ, Goldberg RM, Lucas PC, Nair SG, Shi Q, Sinicrope FA, Wolmark N, Yothers G, Peters U, Newcomb PA, Chan AT. Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. Clin Gastroenterol Hepatol. 2020 Nov; 18 (12):2717-2723.e3 Epub 2019 Dec 04
    View PubMed
  35. Sinicrope FA, Shi Q, Hermitte F, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectr. 2020 Jun; 4 (3):pkaa023 Epub 2020 Apr 05
    View PubMed
  36. Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2020 May; 25 (5):380-e763 Epub 2019 Dec 11
    View PubMed
  37. Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, Andre T, ACCENT Group. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. Eur J Cancer. 2020 May; 130:63-71 Epub 2020 Mar 12
    View PubMed
  38. Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol. 2020 Apr; 31 (4):480-486 Epub 2020 Jan 16
    View PubMed
  39. Lee H, Sha D, Foster NR, Shi Q, Alberts SR, Smyrk TC, Sinicrope FA. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). Ann Oncol. 2020 Apr; 31 (4):487-494 Epub 2020 Jan 25
    View PubMed
  40. Rosen CB, Nagorney DM, Alberts SR. Is There a Role for Liver Transplantation in the Treatment of Patients With Metastatic Colorectal Cancer? Ann Surg 2020 Feb; 271 (2):219-220
    View PubMed
  41. Martinson HA, Mallari D, Richter C, Wu TT, Tiesinga J, Alberts SR, Olnes MJ. Molecular Classification of Gastric Cancer among Alaska Native People. Cancers (Basel). 2020 Jan 13; 12 (1)
    View PubMed
  42. Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. JCO Precis Oncol. 2020; 4 Epub 2020 Feb 26
    View PubMed
  43. Malikowski T, Lehrke HD, Henry MR, Gleeson FC, Alberts SR, Kendrick ML, Lennon RJ, McWilliams RR, Takahashi N, Topazian MD, Gara N, Abu Dayyeh BK, Chandrasekhara V, Chari ST, Iyer PG, Rajan E, Storm AC, Wang KK, Levy MJ. Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Pancreatology. 2020 Jan; 20 (1):110-115 Epub 2019 Nov 14
    View PubMed
  44. Xie H, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Gross GG, Loui WS, Hubbard JM, Alberts SR, Grothey A. Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Ther Adv Med Oncol. 2020; 12:1758835920910913 Epub 2020 Mar 06
    View PubMed
  45. Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, Andre T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019 Sep; 30 (9):1466-1471 Epub 2019 Dec 12
    View PubMed
  46. Song M, Ou FS, Zemla TJ, Hull MA, Shi Q, Limburg PJ, Alberts SR, Sinicrope FA, Giovannucci EL, Van Blarigan EL, Meyerhardt JA, Chan AT. Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). Int J Cancer. 2019 Jul 15; 145 (2):380-389 Epub 2019 Jan 28
    View PubMed
  47. Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julié C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, VAN Jl, Le K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials [submitted]. Proc Am Soc Clin Oncol. 2019.
  48. Cho J, Chen JCY, Paludo J, Conboy EE, Lanpher BC, Alberts SR, Halfdanarson TR. Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review. J Gastrointest Oncol. 2019 Jun; 10 (3):582-588
    View PubMed
  49. Halfdanarson TR, Foster NR, Kim GP, Meyers JP, Smyrk TC, McCullough AE, Ames MM, Jaffe JP, Alberts SR. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). Oncologist. 2019 May; 24 (5):589-e160 Epub 2019 Jan 24
    View PubMed
  50. Sanhueza CT, Huffman BM, Jin Z, Hartgers ML, Smyrk TC, Westin G, McWilliams RR, Ma WW, Alberts SR, Mahipal A. Solid Pseudopapillary Neoplasms of the Pancreas: A Large American Cohort. Pancreas 2019 Apr; 48 (4):e21-e22
    View PubMed
  51. Benson AB III, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang DT, Cloyd J, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Hammond LJ, Darlow SD. Hepatobiliary cancers, version 2.2019 featured updates to the NCCN guidelines Journal Of The National Comprehensive Cancer Network. 2019 Apr; 17 (4):303-10
  52. Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang DT, Cloyd J, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Hammond LJ, Darlow SD. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. J Natl Compr Canc Netw. 2019 Apr 1; 17 (4):302-310
    View PubMed
  53. Levy MJ, Gleeson FC, Topazian MD, Fujii-Lau LL, Enders FT, Larson JJ, Mara K, Abu Dayyeh BK, Alberts SR, Hallemeier CL, Iyer PG, Kendrick ML, Mauck WD, Pearson RK, Petersen BT, Rajan E, Takahashi N, Vege SS, Wang KK, Chari ST. Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone. Clin Gastroenterol Hepatol. 2019 Mar; 17 (4):728-738.e9 Epub 2018 Sept 12
    View PubMed
  54. Kommalapati A, Tella SH, Goyal G, Borad M, Alberts SR, Roberts L, Hubbard JM, Durgin L, Cleary S, Mahipal A. Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. HPB (Oxford). 2019 Mar; 21 (3):379-386 Epub 2018 Sept 25
    View PubMed
  55. Yoon HH, Shi Q, Heying EN, Muranyi A, Bredno J, Ough F, Djalilvand A, Clements J, Bowermaster R, Liu WW, Barnes M, Alberts SR, Shanmugam K, Sinicrope FA. Intertumoral Heterogeneity of CD3(+) and CD8(+) T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis. Clin Cancer Res. 2019 Jan 1; 25 (1):125-133 Epub 2018 Oct 09
    View PubMed
  56. Huffman BM, Westin G, Alsidawi S, Alberts SR, Nagorney DM, Halfdanarson TR, Mahipal A. Survival and Prognostic Factors in Patients With Solid Pseudopapillary Neoplasms of the Pancreas. Pancreas. 2018 Sep; 47 (8):1003-1007
    View PubMed
  57. Martinson HA, Shelby NJ, Alberts SR, Olnes MJ. Gastric cancer in Alaska Native people: A cancer health disparity. World J Gastroenterol. 2018 Jul 7; 24 (25):2722-2732
    View PubMed
  58. Phipps AI, Shi Q, Zemla TJ, Dotan E, Gill S, Goldberg RM, Hardikar S, Jahagirdar B, Limburg PJ, Newcomb PA, Shields A, Sinicrope FA, Sargent DJ, Alberts SR. Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev. 2018 Jun; 27 (6):696-703 Epub 2018 Mar 21
    View PubMed
  59. Jin Z, Hartgers ML, Sanhueza CT, Shubert CR, Alberts SR, Truty MJ, Muppa P, Nagorney DM, Smyrk TC, Hassan M, Mahipal A. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. Eur J Surg Oncol. 2018 May; 44 (5):677-683 Epub 2018 Feb 16
    View PubMed
  60. Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. JAMA Oncol. 2018 Mar 1; 4 (3):379-383
    View PubMed
  61. Kim RD, Alberts SR, Pena C, Genvresse I, Ajavon-Hartmann A, Xia C, Kelly A, Grilley-Olson JE. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. Br J Cancer. 2018 Feb 20; 118 (4):462-470 Epub 2018 Jan 18
    View PubMed
  62. Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10; 35 (32):3671-3677 Epub 2017 Oct 04
    View PubMed
  63. Sinicrope FA, Shi Q, Alberts SR. Mutation in BRAF V600E-Reply. JAMA Oncol 2017 Sep 1; 3 (9):1285-1286
    View PubMed
  64. Levy MJ, Alberts SR, Bamlet WR, Burch PA, Farnell MB, Gleeson FC, Haddock MG, Kendrick ML, Oberg AL, Petersen GM, Takahashi N, Chari ST. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointest Endosc. 2017 Jul; 86 (1):161-169 Epub 2016 Nov 23
    View PubMed
  65. Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouche O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. J Natl Cancer Inst. 2017 May; 109 (5) Epub 2016 Dec 31
    View PubMed
  66. Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017 May 1; 28 (5):1023-1031
    View PubMed
  67. Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 May; 15 (5):563-573
    View PubMed
  68. Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol. 2017 Apr; 12 (2):201-209
    View PubMed
  69. Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol. 2017 Apr 1; 3 (4):472-480
    View PubMed
  70. Miyoshi J, Toden S, Yoshida K, Toiyama Y, Alberts SR, Kusunoki M, Sinicrope FA, Goel A. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep. 2017 Mar 6; 7:43393 Epub 2017 Mar 06
    View PubMed
  71. Renfro LA, Zhang N, Lopatin M, Chao C, Alberts SR. Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer. Clin Colorectal Cancer. 2017 Mar; 16 (1):23-30 Epub 2016 Aug 09
    View PubMed
  72. Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017 Feb 09;
    View PubMed
  73. Jansson-Knodell CL, Foster NR, Sargent DJ, Limburg PJ, Thibodeau SN, Smyrk TC, Sinicrope FA, Jahagirdar B, Goldberg RM, Alberts SR. Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). J Gastrointest Oncol. 2017 Feb; 8 (1):1-11
    View PubMed
  74. Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2016 Dec; 27 (12):2196-2203 Epub 2016 Oct 20
    View PubMed
  75. Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist. 2016 Dec; 21 (12):1509-1521 Epub 2016 Nov 23
    View PubMed
  76. Papamichael D, Renfro LA, Matthaiou C, Yothers G, Saltz L, Guthrie KA, Van Cutsem E, Schmoll HJ, Labianca R, Andre T, O'Connell M, Alberts SR, Haller DG, Kountourakis P, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. J Geriatr Oncol. 2016 Nov; 7 (6):422-429 Epub 2016 July 25
    View PubMed
  77. Wang Y, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Barr Fritcher EG, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, Kipp BR, Zhou J, Barrett MT, Gustafson MP, Alberts SR, Borad MJ, Roberts LR. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Lett. 2016 Sep 28; 380 (1):163-73 Epub 2016 May 20
    View PubMed
  78. Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg M, Nair S, Shields AF, Newcomb PA, Alberts SR, Alliance for Clinical Trials in Oncology. Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. Int J Cancer. 2016 Sep 1; 139 (5):986-95 Epub 2016 May 09
    View PubMed
  79. Sio TT, Martenson JA Jr, Haddock MG, Novotny PJ, Gores GJ, Alberts SR, Miller RC, Heimbach JK, Rosen CB. Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma. Am J Clin Oncol. 2016 Jun; 39 (3):271-5
    View PubMed
  80. Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ. Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol. 2016 Apr 10; 34 (11):1182-9 Epub 2016 Feb 08
    View PubMed
  81. Shah MA, Renfro LA, Allegra CJ, Andre T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J Clin Oncol. 2016 Mar 10; 34 (8):843-53 Epub 2016 Jan 25
    View PubMed
  82. Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26 (3):133-7
    View PubMed
  83. Redwood DG, Asay ED, Blake ID, Sacco PE, Christensen CM, Sacco FD, Tiesinga JJ, Devens ME, Alberts SR, Mahoney DW, Yab TC, Foote PH, Smyrk TC, Provost EM, Ahlquist DA. Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. Mayo Clin Proc. 2016 Jan; 91 (1):61-70 Epub 2015 Oct 28
    View PubMed
  84. Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015 Dec 1; 21 (23):5294-304 Epub 2015 July 17
    View PubMed
  85. Bhat M, Hathcock M, Kremers WK, Darwish Murad S, Schmit G, Martenson J, Alberts S, Rosen CB, Gores GJ, Heimbach J. Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol. Transpl Int. 2015 Dec; 28: (12)1383-91.
    View PubMed
  86. Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J Natl Cancer Inst. 2015 Oct; 107 (10) Epub 2015 July 09
    View PubMed
  87. Cheville AL, Alberts SR, Rummans TA, Basford JR, Lapid MI, Sloan JA, Satele DV, Clark MM. Improving Adherence to Cancer Treatment by Addressing Quality of Life in Patients With Advanced Gastrointestinal Cancers. J Pain Symptom Manage. 2015 Sep; 50 (3):321-7 Epub 2015 May 12
    View PubMed
  88. Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 2015 Aug 20; 33 (24):2617-22 Epub 2015 May 11
    View PubMed
  89. Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR, Goel A. MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer. 2015 Jun 30; 113 (1):83-90 Epub 2015 June 02
    View PubMed
  90. Renfro LA, Grothey A, Kerr D, Haller DG, Andre T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general populationdagger. Ann Oncol. 2015 May; 26 (5):950-958 Epub 2015 Feb 19
    View PubMed
  91. Wi CI, Loo NM, Larson JJ, Moynihan TJ, Madde NR, Grendahl DC, Alberts SR, Kim WR. Low level of hepatitis B virus screening among patients receiving chemotherapy. Clin Gastroenterol Hepatol. 2015 May; 13 (5):970-5; quiz e51 Epub 2014 Nov 06
    View PubMed
  92. Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015 Jan; 148 (1):88-99 Epub 2014 Oct 08
    View PubMed
  93. Renfro LA, Grothey A, Xue Y, Saltz LB, Andre T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst. 2014 Dec; 106 (12) Epub 2014 Oct 29
    View PubMed
  94. Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014 Dec; 106 (12) Epub 2014 Nov 07
    View PubMed
  95. Alberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim GP, Mazurczak MA, Hornberger J. Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer. Pharmacoeconomics. 2014 Dec; 32 (12):1231-43
    View PubMed
  96. Philip PA, Chansky K, LeBlanc M, Rubinstein L, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. Clin Cancer Res. 2014 Aug 15; 20 (16):4176-85 Epub 2014 June 09
    View PubMed
  97. Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C, Alberts SR. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs. 2014 Aug; 32 (4):710-6 Epub 2014 Apr 18
    View PubMed
  98. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014 Jul; 106 (7) Epub 2014 June 12
    View PubMed
  99. Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res. 2014 Jun 15; 20 (12):3319-27 Epub 2014 Apr 11
    View PubMed
  100. Hochster HS, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, Chowhan N, Ramanathan RK, Keaton M, Hainsworth JD, Childs BH. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014 Jun; 25 (6):1172-8 Epub 2014 Mar 07
    View PubMed
  101. Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 2014 Jun; 13 (2):100-9 Epub 2013 Dec 28
    View PubMed
  102. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014 Jun 1; 20 (11):3033-43 Epub 2014 Mar 31
    View PubMed
  103. Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim G, Mazurczak M, Lee M, Alberts SR. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist. 2014 May; 19 (5):492-7 Epub 2014 Apr 07
    View PubMed
  104. Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buyse M, Burzykowski T, GASTRIC group. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst. 2013 Nov 6; 105 (21):1600-7 Epub 2013 Oct 09
    View PubMed
  105. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013 Oct 10; 31 (29):3664-72 Epub 2013 Sept 09
    View PubMed
  106. Cheung WY, Shi Q, O'Connell M, Cassidy J, Blanke CD, Kerr DJ, Meyers J, Van Cutsem E, Alberts SR, Yothers G, Sargent DJ, ACCENT Collaborative Group. The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Clin Colorectal Cancer. 2013 Sep; 12(3):179-87. Epub 2013 Jun 27
    View PubMed
  107. Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013 Aug; 20(8):2787-95. Epub 2013 Feb 23.
    View PubMed
  108. Sinicrope FA, Smyrk TC, Tougeron D, Thibodeau SN, Singh S, Muranyi A, Shanmugam K, Grogan TM, Alberts SR, Shi Q. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer. 2013 Aug 1; 119 (15):2765-70 Epub 2013 May 08
    View PubMed
  109. Sticca RP, Alberts SR, Mahoney MR, Sargent DJ, Finstuen LM, Nelson GD, Husted TM, Franko J, Goldman CD, Pockaj BA. Current use and surgical efficacy of laparoscopic colectomy in colon cancer. J Am Coll Surg. 2013 Jul; 217(1):56-62; discussion 62-3. Epub 2013 Apr 24.
    View PubMed
  110. Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Narayanan Menon KV, Larusso NF, Alberts SR, Gores GJ, Fleming CJ, Slettedahl SW, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC, Roberts LR. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013 Jun; 36 (3):714-23 Epub 2012 Oct 24
    View PubMed
  111. Phipps AI, Shi Q, Newcomb PA, Nelson GD, Sargent DJ, Alberts SR, Limburg PJ. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. J Clin Oncol. 2013 Jun 1; 31(16):2016-23. Epub 2013 Apr 01.
    View PubMed
  112. Hubbard JM, Alberts SR. Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastrointest Cancer Res. 2013 Mar; 6 (2):47-55
    View PubMed
  113. Alberts SR. Update on the optimal management of patients with colorectal liver metastases. Crit Rev Oncol Hematol. 2012 Oct; 84 (1):59-70 Epub 2012 Mar 17
    View PubMed
  114. Alberts SR, Reid JM, Morlan BW, Farr GH Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol. 2012 Oct; 35 (5):418-23
    View PubMed
  115. Darwish Murad S, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, Alberts SR, Heimbach JK. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology. 2012 Sep; 56 (3):972-81 Epub 2012 July 17
    View PubMed
  116. Kelly JJ, Alberts SR, Sacco F, Lanier AP. Colorectal cancer in alaska native people, 2005-2009. Gastrointest Cancer Res. 2012 Sep; 5(5):149-54.
    View PubMed
  117. Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, Nair S. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol. 2012 Aug; 35 (4):329-33
    View PubMed
  118. Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, Novotny PJ, Alberts SR, Limburg PJ, Pittelkow MR. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer. 2012 Apr 15; 118 (8):2128-37 Epub 2011 Aug 31
    View PubMed
  119. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012 Apr 4; 307 (13):1383-93
    View PubMed
  120. Alberts SR, Kelly JJ, Ashokkumar R, Lanier AP. Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973-2007. Int J Circumpolar Health. 2012 Mar 20; 71:17521
    View PubMed
  121. Bolton JS, O'Connell MJ, Mahoney MR, Farr GH, Fitch TR, Maples WJ, Nagorney DM, Rubin J, Fuloria J, Steen PD, Alberts SR. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clin Colorectal Cancer. 2012 Mar; 11(1):31-7. Epub 2011 May 13.
    View PubMed
  122. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20; 30 (3):263-7 Epub 2011 Dec 12
    View PubMed
  123. Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Menon KVN, La Russo NF, Alberts SR, Gores GJ, Fleming CJ, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC, Roberts LR. Transarterial Radioembolization Provided Equivalent Overall Survival but Required Few Treatments and is Better Tolerated than Chemoembolization in Patients with Hepatocellular Carcinoma. J Clin Oncol.2012;
  124. Alberts SR, Poston GJ. Treatment advances in liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2011 Dec; 10(4):258-65. Epub 2011 Aug 05.
    View PubMed
  125. Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011 Nov 1; 29(31):4105-12. Epub 2011 Oct 03.
    View PubMed
  126. Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, Speers C, Alberts SR, Bardia A, O'Connell MJ, Sargent DJ. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer. 2011 Sep 15; 117(18):4155-65. Epub 2011 Mar 01.
    View PubMed
  127. Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, O'Rourke M, Perry MC, Goldberg RM, Mayer RJ, Colacchio TA. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol. 2011 Aug 10; 29(23):3146-52. Epub 2011 Jul 11.
    View PubMed
  128. Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A, Adjuvant Colon Cancer End-points (ACCENT) Group. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer. 2011 May; 47 (7):990-6 Epub 2011 Jan 21
    View PubMed
  129. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011 Feb 1; 29 (4):421-7 Epub 2010 Dec 28
    View PubMed
  130. Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW, ACCENT Collaborative Group. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. JNCI. 2011; 103(20):1498-506.
  131. Haddock MG, Miller RC, Nelson H, Pemberton JH, Dozois EJ, Alberts SR, Gunderson LL. Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys. 2011 Jan 1; 79 (1):143-50 Epub 2010 Apr 13
    View PubMed
  132. Jatoi A, Soori G, Foster NR, Hiatt BK, Knost JA, Fitch TR, Callister MD, Nichols FC 3rd, Husted TM, Alberts SR. Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors. J Thorac Oncol. 2010 Dec; 5 (12):1994-8
    View PubMed
  133. Novotny PJ, Smith DJ, Guse L, Smith DJ, Rummans TA, Hartmann L, Alberts S, Goldberg R, Gregory D, Johnson M, Sloan JA. A pilot study assessing social support among cancer patients enrolled on clinical trials: a comparison of younger versus older adults. Cancer Manag Res. 2010 May 27; 2:133-42
    View PubMed
  134. Hubbard JM, Alberts SR. Treatment of liver-limited metastatic colorectal cancer. Cancer J. 2010 May-Jun; 16(3):235-40.
    View PubMed
  135. Bardia A, Greeno E, Miller R, Alberts S, Dozois E, Haddock M, Limburg P. Is a solitary inguinal lymph node metastasis from adenocarcinoma of the rectum really a metastasis? Colorectal Dis. 2010 Apr; 12(4):312-5. Epub 2009 Feb 25.
    View PubMed
  136. Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR, Alberts SR. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol. 2010 Mar; 36 (3):601-6
    View PubMed
  137. Alberts SR, Roh MS, Mahoney MR, O'Connell MJ, Nagorney DM, Wagman L, Smyrk TC, Weiland TL, Lai LL, Schwarz RE, Molina R, Dentchev T, Bolton JS. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol. 2010 Feb 10; 28 (5):853-8 Epub 2010 Jan 04
    View PubMed
  138. Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S, Sargent D. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. Semin Oncol. 2010 Feb; 37(1):39-46.
    View PubMed
  139. de Gramont, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010 Jan 20; 28(3):460-5. Epub 2009 Dec 14.
    View PubMed
  140. Small AJ, Alberts SR, Baron TH. Response. Gastrointest Endosc. 2010; 72(6):1330-2.
  141. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat. 2009 Oct; 117 (3):603-9 Epub 2009 Feb 12
    View PubMed
  142. Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res. 2009 Sep 15; 15 (18):5937-44 Epub 2009 Sept 01
    View PubMed
  143. Cicek MS, Slager SL, Achenbach SJ, French AJ, Blair HE, Fink SR, Foster NR, Kabat BF, Halling KC, Cunningham JM, Cerhan JR, Jenkins RB, Boardman LA, Petersen GM, Sargent DJ, Alberts SR, Limburg PJ, Thibodeau SN. Functional and clinical significance of variants localized to 8q24 in colon cancer. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2492-500. Epub 2009 Aug 18.
    View PubMed
  144. McJoynt TA, Hirzallah MA, Satele DV, Pitzen JH, Alberts SR, Rajkumar SV. Building a protocol expressway: the case of Mayo Clinic Cancer Center. J Clin Oncol. 2009 Aug 10; 27 (23):3855-60 Epub 2009 June 29
    View PubMed
  145. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Aug 10; 27(23):3778-85. Epub 2009 Jul 06.
    View PubMed
  146. Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009 Jun 10; 27 (17):2848-54 Epub 2009 Apr 20
    View PubMed
  147. Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin Colorectal Cancer. 2009 Apr; 8 (2):88-93
    View PubMed
  148. Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. Clin Colorectal Cancer. 2009 Mar; 8(2):88-93.
    View PubMed
  149. Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology. 2009; 77 (2):120-3 Epub 2009 July 22
    View PubMed
  150. Taieb J, Laurent-Puig P, Alberts S. Incidence of KRAS status in ongoing adjuvant trials in colon cancer. Curr Colorectal Cancer Rep. 2009; 5:171-8.
  151. Shah A, Alberts S, Adam R. Accomplishments in 2007 in the management of curable metastatic colorectal cancer. Gastrointest Cancer Res. 2009; 2(suppl 3):s13-8.
  152. Alberts SR. Do we need biologic agents in preoperative systemic therapy of liver metastases? Current Colorectal Cancer Reports. 2009; 5(2):114-9.
  153. Mincey B, Dentchev T, Sloan J, Hines S, Perez E, Johnson D, Schaefer P, Alberts S, Liu H, Wender D, Mazurczak M, Nikcevich D, Loprinzi C. Immediate vs. Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole After Tamoxifen - N03CC. Breast Cancer Res Treat. 2009; 117:603-9.
  154. Alberts S, Roh M, Mahoney M, O'Connell M, Nagorney D, Wagman L, Smyrk T, Weiland T, Lai L, Schwarz R, Molina R, Dentchev T, Bolton J. Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases from Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66. JCO. 2009.
  155. Alberts SR. Updated options for liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2008 Dec; 7 Suppl 2:S58-62.
    View PubMed
  156. Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL, Sargent DJ, Sloan JA, Buckner JC, North Central Cancer Treatment Group. North Central Cancer Treatment Group--achievements and perspectives. Semin Oncol. 2008 Oct; 35 (5):530-44
    View PubMed
  157. Alberts SR, Wagman LD. Chemotherapy for colorectal cancer liver metastases. Oncologist. 2008 Oct; 13(10):1063-73. Epub 2008 Oct 06.
    View PubMed
  158. Sinicrope FA, Rego RL, Foster NR, Thibodeau SN, Alberts SR, Windschitl HE, Sargent DJ. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res. 2008 Jul 1; 14 (13):4128-33
    View PubMed
  159. Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM Jr, Moore DF Jr, Jaslowski AJ, Thomas SP, Hauge MD, Flynn PJ, Stella PJ, Alberts SR. Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol. 2008 May; 3 (5):516-20
    View PubMed
  160. Galanis E, Carlson SK, Foster NR, Lowe V, Quevedo F, McWilliams RR, Grothey A, Jatoi A, Alberts SR, Rubin J. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol Ther. 2008 May; 16 (5):979-84 Epub 2008 Mar 18
    View PubMed
  161. Gines A, Cassivi SD, Martenson JA Jr, Schleck C, Deschamps C, Sinicrope FA, Alberts SR, Murray JA, Zinsmeister AR, Vazquez-Sequeiros E, Nichols FC 3rd, Miller RC, Quevedo JF, Allen MS, Alexander JA, Zais T, Haddock MG, Romero Y. Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus. 2008; 21 (3):241-50
    View PubMed
  162. Katipamula R, Jatoi A, Foster NR, Nichols F, Rubin J, Callister M, Gunderson L, Alberts S. Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E. Clin Med Oncol. 2008; 2:223-5 Epub 2008 Apr 01
    View PubMed
  163. Alberts SR, Sande JR, Foster NR, Quevedo FJ, McWilliams RR, Kugler JW, Fitch TR, Jaslowski AJ. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II trial, N9943. J Gastrointest Cancer. 2008; 38(2-4):87-94.
  164. Alberts SR. Use of neoadjuvant and postoperative chemotherapy with surgical resection of colorectal liver metastases. Curr Colorectal Cancer Rep. 2008; 4:100-5.
  165. Kim G, Foster N, Oberg A, Jaslowksi A, Alberts S, Flynn P, Dakhil S, Mowat R, Garneau S. NCCTG Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma, N034A. J Clin Oncol. 2008.
  166. Jatoi A, Martenson JA, Foster NR, McLeod HL, Lair BS, Nichols F, Tschetter LK, Moore DF Jr, Fitch TR, Alberts SR, North Central Cancer Treatment Group (N0044). Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol. 2007 Oct; 30(5):507-13.
    View PubMed
  167. Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, Ishitani MB, Andrews JC, McKusick MA, Haddock MG, Alberts SR, Gores GJ. Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl. 2007 Oct; 13(10):1372-81.
    View PubMed
  168. Alberts SR. Therapeutic Advances in GI Malignancies--Fifth Annual Conference. 13-14 July 2007, Newport Beach, CA, USA. IDrugs. 2007 Oct; 10 (10):693-5
    View PubMed
  169. Dy GK, Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pockaj BA, Sticca RP, Alberts SR, Pitot HC 4th, Goldberg RM, Intergroup N9741. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol. 2007 Aug 10; 25 (23):3469-74
    View PubMed
  170. Ashley AC, Sargent DJ, Alberts SR, Grothey A, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer. 2007 Aug 1; 110(3):670-7.
    View PubMed
  171. Alberts SR, Kim GP, Mahoney MR, Gornet MK, Rubin J, Ames M, Goetz MP, Weinshilboum RM, Nicol SJ, Goldberg RM. Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248. Clin Colorectal Cancer. 2007 Jul; 6 (8):572-7
    View PubMed
  172. Haddock MG, Swaminathan R, Foster NR, Hauge MD, Martenson JA, Camoriano JK, Stella PJ, Tenglin RC, Schaefer PL, Moore DF Jr, Alberts SR. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol. 2007 Jun 20; 25 (18):2567-72
    View PubMed
  173. Alberts SR, Gores GJ, Kim GP, Roberts LR, Kendrick ML, Rosen CB, Chari ST, Martenson JA. Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc. 2007 May; 82 (5):628-37
    View PubMed
  174. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007 Apr 20; 25(12):1539-44.
    View PubMed
  175. Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2007 Feb; 59(2):207-15. Epub 2006 Jun 09.
    View PubMed
  176. Alberts SR, Sande JR, Foster NR, Quevedo FJ, McWilliams RR, Kugler JW, Fitch TR, Jaslowski AJ. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. J Gastrointest Cancer. 2007; 38 (2-4):87-94 Epub 2008 Nov 21
    View PubMed
  177. Alberts SR, Suman VJ, Pitot HC, Camoriano JK, Rubin J. Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. J Gastrointest Cancer. 2007; 38 (1):10-4
    View PubMed
  178. Jatoi A, Dakhil S, Foster N, Ma C, Rowland K, Moore D, Jaslowksi A, Thomas S, Hauge M, Flynn P, Stella P, Alberts S. Bortezobim, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients With Metastatic Esophageal Cancer: Phase II Results from the NCCTG (N044B). J Thorac Oncol. 2007; 3(5):516-20.
  179. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation. 2006 Dec 27; 82(12):1703-7.
    View PubMed
  180. Patiyil S, Alberts SR. Metastatic colorectal cancer: Therapeutic options. Curr Treat Options Oncol. 2006 Sep; 7 (5):389-98
    View PubMed
  181. Moreno-Aspitia A, Colon-Otero G, Hoering A, Tefferi A, Niedringhaus RD, Vukov A, Li CY, Menke DM, Geyer SM, Alberts SR, North Central Cancer Treatment Group. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer. 2006 Aug 15; 107(4):767-72.
    View PubMed
  182. Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2006 Aug; 58 (2):165-72 Epub 2005 Nov 19
    View PubMed
  183. Kelly JJ, Lanier AP, Alberts S, Wiggins CL. Differences in cancer incidence among Indians in Alaska and New Mexico and U.S. Whites, 1993-2002. Cancer Epidemiol Biomarkers Prev. 2006 Aug; 15(8):1515-9.
    View PubMed
  184. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol. 2006 Jul 20; 24(21):3347-53.
    View PubMed
  185. Alberts SR, Novotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ, Blute ML, Fitch TR, Levitt R, Lieberman R, Loprinzi CL. Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial. Am J Ther. 2006 Jul-Aug; 13 (4):291-7
    View PubMed
  186. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006 Jun; 81 (6):758-67
    View PubMed
  187. Alberts SR. Neoadjuvant therapy in initially not resectable liver metastases from colorectal cancer: North Central Cancer Treatment Group (NCCTG) Trial 97-46-51. American Journal of Oncology Review. 2006 May; 5(5):290-2.
  188. Ashley AC, Deschamps C, Alberts SR. Impact of prognostic factors on clinical outcome after resection of colorectal pulmonary metastases. Clin Colorectal Cancer. 2006 May; 6(1):32-7.
    View PubMed
  189. Giordano KF, Jatoi A, Stella PJ, Foster N, Tschetter LK, Alberts SR, Dakhil SR, Mailliard JA, Flynn PJ, Nikcevich DA, North Central Cancer Treatment Group. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006 Apr; 17 (4):652-6 Epub 2006 Feb 23
    View PubMed
  190. Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, Alberts SR, Kaur JS, Perez EA, NCCTG. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Ann Oncol. 2006 Apr; 17 (4):623-9 Epub 2006 Mar 06
    View PubMed
  191. Alberts SR, Kelly JJ, Lanier AP, Sacco F. Occurrence of esophageal and gastric cancer in Alaska Natives, 1969-2003. Alaska Med. 2006 Apr-Jun; 48 (1):2-11
    View PubMed
  192. Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM Jr, Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol. 2006 Mar 1; 24 (7):1079-89
    View PubMed
  193. Alberts SR. Neoadjuvant and adjuvant therapy combined with resection of hepatic colorectal cancer metastases. Current Colorectal Cancer Reports. 2006; 2(2):81-4.
  194. Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM Jr, North Central Cancer Treatment Group. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006 Jan; 17 (1):29-34 Epub 2005 Nov 22
    View PubMed
  195. Miller RC, Haddock MG, Gunderson LL, Donohue JH, Trastek VF, Alberts SR, Deschamps C. Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas. Dis Esophagus. 2006; 19: (6)487-95.
    View PubMed
  196. Dy GK, Alberts SR. Recent advances in the treatment of metastatic colorectal cancer. Hospital Pharmacy Europe. 2006.
  197. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20; 23(36):9243-9. Epub 2005 Oct 17.
    View PubMed
  198. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJN, Cornelis M, Kahan JP. OncoSurge: A strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005 Oct 1; 23(28):7125-34.
    View PubMed
  199. Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, Lathia CD, Alberts SR. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs. 2005 Oct; 16 (9):997-1002
    View PubMed
  200. Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, Fitch TR, Steen P, Kim GP, Gill S. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol. 2005 Oct; 16 (10):1654-61 Epub 2005 Aug 05
    View PubMed
  201. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005 Sep; 242 (3):451-8; discussion 458-61
    View PubMed
  202. Alberts SR, Sinicrope FA, Grothey A. N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer. 2005 Sep; 5 (3):211-3
    View PubMed
  203. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005 Aug; 16(8):1311-9.
    View PubMed
  204. Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 Jun; 55 (6):522-30 Epub 2005 Mar 08
    View PubMed
  205. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs. 2005 Jun; 23 (3):257-61
    View PubMed
  206. Jatoi A, Alberts SR, Foster N, Morton R, Burch P, Block M, Nguyen PL, Kugler J, North Central Cancer Treatment Group. Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Support Care Cancer. 2005 Jun; 13 (6):381-6 Epub 2005 Mar 10
    View PubMed
  207. Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res. 2005 May 1; 11 (9):3410-6
    View PubMed
  208. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005 Apr 20; 23(12):2606-17. Epub 2004 Sep 27.
    View PubMed
  209. Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005 Mar; 16 (3):425-9 Epub 2005 Jan 27
    View PubMed
  210. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Fitch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2005 Jan 1; 103 (1):111-8
    View PubMed
  211. Alberts S, Horvath W, Sternfeld W, Goldberg R, Mahoney M, Dakhil S, Levitt R, Rowland K, Nair S, Sargent D, Donohue J. Oxalplatin, 5-Fluorouracil, And Leucovorin (FOLFOX4) For Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG) Phase II Study J Clin Oncol. 2005; 23:9243-9249.
  212. Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF Jr, Rowland KM Jr, Nair S, Tschetter LK, Fitch TR. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol. 2004 Dec 15; 22 (24):4944-50
    View PubMed
  213. Jatoi A, Martenson J, Mahoney MR, Lair BS, Brindle JS, Nichols F, Caron N, Nichols F, Rowland K, Tschetter L, Alberts S. Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations from the North Central Cancer Treatment Group. Int Semin Surg Oncol. 2004 Nov 8; 1 (1):9 Epub 2004 Nov 08
    View PubMed
  214. Gores GJ, Baskin-Bey ES, Baron TH, Alberts SR. Treatment endpoints for advanced cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2004 Nov; 1(1):4-5.
    View PubMed
  215. Heimbach JK, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB, Gores GJ. Transplantation for hilar cholangiocarcinoma. Liver Transpl. 2004 Oct; 10(10 Suppl 2):S65-8.
    View PubMed
  216. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004 May 15; 22 (10):1797-806 Epub 2004 Apr 05
    View PubMed
  217. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004 May; 24(2):201-7.
    View PubMed
  218. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004 Jan 1; 22(1):23-30. Epub 2003 Dec 09.
    View PubMed
  219. Witzig T, Silberstein P, Loprinzi C, Sloan J, Novotny P, Mailliard J, Rowland K, Alberts S, Nikcevich D, Levitt R, Morton R. A Phase III Randomized Double-Blind Study of Epoetin alfa Versus Placebo in Anemic Patients with Cancer Undergoing Chemotherapy J Clin Oncol. 2004; 22:1-12.
  220. Alberts S, Poston G, Alberts S. OncoSurge: a strategy for long-term survival in metastatic colorectal cancer. Colorectal Dis. 2003 Nov; 5 Suppl 3:20-8
    View PubMed
  221. Jatoi A, Suman VJ, Schaefer P, Block M, Loprinzi C, Roche P, Garneau S, Morton R, Stella PJ, Alberts SR, Pittelkow M, Sloan J, Pagano R. A phase II study of topical ceramides for cutaneous breast cancer. Breast Cancer Res Treat. 2003 Jul; 80(1):99-104.
    View PubMed
  222. Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003 Jul; 9 (7):2520-6
    View PubMed
  223. Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Moore DF, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, Mailliard JA. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol. 2003 Apr; 14 (4):580-5
    View PubMed
  224. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003; 14 Suppl 2:ii31-6
    View PubMed
  225. Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton PJ, Watanabe T, Geary RS, Holmlund J, Dorr FA. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res. 2003 Jan; 9 (1):115-23
    View PubMed
  226. Markovic S, Suman V, Dalton R, Allred J, Wettstein P, Nevala W, Celis E, Alberts S, Fitch T, Egner J, Ebberts L, Tschetter L. A Phase II Study of Aerosolized GM-CSF in the Treatm Cancer. 2003.
  227. Goldberg RM, Kaufmann SH, Atherton P, Sloan JA, Adjei AA, Pitot HC, Alberts SR, Rubin J, Miller LL, Erlichman C. A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. Ann Oncol. 2002 Oct; 13 (10):1674-80
    View PubMed
  228. Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Ruben S, Boemer SA, Atherton P, Ames MM, Kaufmann SH. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Invest New Drugs. 2002 Aug; 20 (3):297-304
    View PubMed
  229. Markovic SN, Suman VJ, Vukov AM, Fitch TR, Hillman DW, Adjei AA, Alberts SR, Kaur JS, Braich TA, Leitch JM, Creagan ET. Phase II trial of KW2189 in patients with advanced malignant melanoma. Am J Clin Oncol. 2002 Jun; 25 (3):308-12
    View PubMed
  230. Alberts SR, Townley PM, Goldberg RM, Cha SS, Moore DF Jr, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, Mailliard JA, Sargent DJ. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Ann Oncol. 2002 Apr; 13 (4):553-7
    View PubMed
  231. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol. 2002 Mar 15; 20: (6)1683-91.
    View PubMed
  232. Jatoi A, Tirona MT, Cha SS, Alberts SR, Rowland KM, Morton RF, Nair S, Kardinal CG, Stella PJ, Mailliard JA, Sargen D, Goldberg RM. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer. 2002; 32 (2-3):115-23
    View PubMed
  233. Alberts SR, Fishkin PA, Burgart LJ, Cera PJ, Mahoney MR, Morton RF, Johnson PA, Nair S, Goldberg RM, North Central Cancer Treatment Group. CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer. 2002; 32 (2-3):107-14
    View PubMed
  234. Sellers TA, Alberts SR, Vierkant RA, Grabrick DM, Cerhan JR, Vachon CM, Olson JE, Kushi LH, Potter JD. High-folate diets and breast cancer survival in a prospective cohort study. Nutr Cancer. 2002; 44(2):139-44.
    View PubMed
  235. Jacobson SD, Alberts SR, O'Connell MJ. Pancreatic cancer in the older patient. Oncology (Williston Park). 2001 Jul; 15 (7):926-32; discussion 935-7
    View PubMed
  236. Alberts SR, Erlichman C, Sloan J, Okuno SH, Burch PA, Rubin J, Pitot HC, Goldberg RM, Adjei AA, Atherton PJ, Kaufmann SH. Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks. Ann Oncol. 2001 May; 12 (5):627-31
    View PubMed
  237. Alberts SR, Blute ML. Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia. Urology. 2001 Apr; 57 (4 Suppl 1):188-90
    View PubMed
  238. Erlichman C, Adjei AA, Alberts SR, Sloan JA, Goldberg RM, Pitot HC, Rubin J, Atherton PJ, Klee GG, Humphrey R. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol. 2001 Mar; 12 (3):389-95
    View PubMed
  239. Alberts S. Evolving medical therapy for stomach cancer. Oncologia Clinica. 2001.
  240. Alberts S. Evolving medical therapy for esophageal cancer. Oncologia Clinica. 2001.
  241. Alberts SR. Intrahepatic therapy for resected hepatic metastases from colorectal carcinoma. Oncology (Williston Park). 2000 Dec; 14 (12 Suppl 11):48-51
    View PubMed
  242. Galanis E, Alberts SR, O'Connell MJ. New adjuvant therapy for colon cancer: justified hope or commercial hype. Surg Oncol Clin N Am. 2000 Oct; 9(4):813-23; discussion 825-6.
    View PubMed
  243. Wagner JC, Alberts SR. RESPONSE: patient costs on clinical trials. J Natl Cancer Inst. 2000 Sep 6; 92(17):1442-3.
    View PubMed
  244. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol. 2000 Apr; 18 (8):1748-57
    View PubMed
  245. Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol. 2000 Mar; 18 (5):1116-23
    View PubMed
  246. Loprinzi CL, Alberts SR, Christensen BJ, Hanson LJ, Farley DR, Broers JK, Betcher DL, Grady RE, Southorn PA, Johnson TM, Perez EA. History of the development of antiemetic guidelines at Mayo Clinic Rochester. Mayo Clin Proc. 2000 Mar; 75 (3):303-9
    View PubMed
  247. Porrata LF, Alberts S, Alberts S, Hook C, Hanson CA. Idiopathic thrombocytopenic purpura associated with breast cancer: a case report and review of the current literature. Am J Clin Oncol. 1999 Aug; 22 (4):411-3
    View PubMed
  248. Wagner JL, Alberts SR, Sloan JA, Cha S, Killian J, O'Connell MJ, Van Grevenhof P, Lindman J, Chute CG. Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst. 1999 May 19; 91(10):847-53.
    View PubMed
  249. Alberts SR, Bretscher M, Wiltsie JC, O'Neill BP, Mokri B, Witzig TE. Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Leuk Lymphoma. 1999 Feb; 32 (5-6):489-96
    View PubMed
  250. Alberts SR, Erlichman C, Reid JM, Sloan JA, Ames MM, Richardson RL, Goldberg RM. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin Cancer Res. 1998 Sep; 4(9):2111-7.
    View PubMed
  251. Alberts SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr GH Jr, Krook JE, Wieand HS. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer. 1996 Aug 15; 78: (4)764-72.
    View PubMed
  252. Alberts SR, Erlichman C. Adjuvant therapy for colon cancer: a review of current approaches and future directions. Seminars in Colon & Rectal Surgery. 1996; 7(1):40-46.
  253. Lanier AP, Alberts SR. Malignant neoplasms of the lymphatic and haematopoietic system in Circumpolar Inuit. Acta Oncol. 1996; 35(5):601-6.
    View PubMed
  254. Lanier AP, Alberts SR. Kidney and bladder cancer in Inuit 1969-1988. Acta Oncol. 1996; 35(5):595-9.
    View PubMed
  255. Lanier AP, Alberts SR. Cancers of the buccal cavity and pharynx in Circumpolar Inuit. Acta Oncol. 1996; 35(5):545-52.
    View PubMed
  256. Strickler JG, Zheng J, Shu Q, Burgart LJ, Alberts SR, Shibata D. p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res. 1994 Sep 1; 54(17):4750-5.
    View PubMed
  257. Alberts SR, Lanier AP, McMahon BJ, Harpster A, Bulkow LR, Heyward WL, Murray C. Clustering of hepatocellular carcinoma in Alaska Native families. Genet Epidemiol. 1991; 8(2):127-39.
    View PubMed
  258. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 1990 May; 150(5):1051-4.
    View PubMed
  259. Popper H, Thung SN, McMahon BJ, Lanier AP, Hawkins I, Alberts SR. Evolution of hepatocellular carcinoma associated with chronic hepatitis B virus infection in Alaskan Eskimos. Archives of Pathology & Laboratory Medicine. 1988 May; 112(5):498-504.
    View PubMed
  260. Lanier AP, McMahon BJ, Alberts SR, Popper H, Heyward WL. Primary liver cancer in Alaskan Natives. 1980-1985. Cancer. 1987 Oct 15; 60(8):1915-20.
    View PubMed
  261. Alberts SR, Lanier AP. Leukemia, lymphoma, and multiple myeloma in Alaskan Natives. J Natl Cancer Inst. 1987 May; 78(5):831-7.
    View PubMed
PST-20217411